With its first-quarter earnings release on Thursday, investors are finally seeing signs of a bright future at Energy Transfer Partners (NYSE: ETP ) . Adjusted EBITDA grew $462 million year over year, and revenue blew past expectations, coming in at approximately $10.9 billion.
As management continues to simplify the structure at ETP -- which requires moving assets between Energy Transfer Equity (NYSE: ETE ) �and theoretically Sunoco Logistics Partners (NYSE: SXL ) -- year-over-year comparisons will be full of asterisks indicating earnings from the previous structure, as well as the one-time charges we are accustomed to seeing. With that in mind, today I'm focusing primarily on ETP from an operations and progress perspective, highlighting three key areas investors should take away from the first quarter.
1. Growth�
ETP's Midstream unit turned in an excellent performance on the back of increasing production in the Eagle Ford Shale. NGL production was way up on ETP's legacy assets, and fee-based revenue in this segment climbed from $70 million to $97 million year over year. The bulk of that, some $22 million, can be attributed solely to growth in the Eagle Ford.
Best Blue Chip Companies To Buy For 2015: Stemline Therapeutics Inc (STML)
Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.
SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.
SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk
SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.
SL-701
SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.
StemScreen-1
StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.
StemScreen-2
StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.
The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.
Advisors' Opinion:- [By Keith Speights]
Best-performing biotech IPO
Stemline Therapeutics� (NASDAQ: STML ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%. - [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
Top Logistics Stocks To Watch Right Now: Reliance Industries Ltd (RELIANCE)
Reliance Industries Limited (RIL) is a conglomerate with business in the energy and materials value chain. The Company operates in three segments: petrochemicals, refining and oil & gas. The petrochemicals segment includes production and marketing operations of petrochemical products which include, polyethylene, polypropylene, polyvinyl chloride, poly butadiene rubber, polyester yarn, polyester fibre, purified terephthalic acid, paraxylene, ethylene glycol, olefins, aromatics, linear alkyl benzene, butadiene, acrylonitrile, caustic soda and polyethylene terephthalate. The refining segment includes production and marketing operations of the petroleum products. The oil and gas segment includes exploration, development and production of crude oil and natural gas. Its others segment includes textile, retail business, special economic zone (SEZ) development and telecom / broadband business. Advisors' Opinion:- [By MONEYMORNING.COM]
Vanguard favors India with investments in Infosys Ltd. (NSE: INFY), Reliance Industries Ltd. (NSE: RELIANCE), and Housing Development Finance Corp. Ltd. (NSE: HDFC) ranking among its top 20.
Top Logistics Stocks To Watch Right Now: Neenah Paper Inc. (NP)
Neenah Paper, Inc. produces technical products and fine papers worldwide. The company�s Technical Products segment provides filtration media for applications in automotive transportation; saturated and unsaturated crepe and flat paper tapes to manufacturers; lightweight abrasive paper for waterproof and dry sanding applications; wall covering substrates to converters serving commercial and consumer-do-it-yourself markets; label and tag products to pressure sensitive coaters; latex saturated and coated papers; premask, medical packaging, image transfer, and decorative components papers; and other products, such as clean room papers, durable printing papers, release papers, and furniture backers. Its Fine Paper segment manufactures and sells writing papers used for business and personal stationery, corporate identity packages, and related end-use applications; text and cover papers and envelopes used in corporate brochures, pocket folders, corporate annual reports, advertis ing inserts, direct mail, business cards, hang tags, scrapbooks, and various other uses; custom colors, paper finishes, and duplex/laminated papers; and bright papers used in direct mail, advertising inserts, scrapbooks, and marketing collateral applications. This segment also offers other specialty papers for various applications in wine labels and luxury packaging, as well as specialty paper products for enhanced image, such as translucent and art papers, papers for optical scanning, and other specialized applications. Neenah Paper, Inc. markets its products primarily under the JET-PRO, SofStretch, KIMDURA, MUNISING LP, PREVAIL, NEENAH, GESSNER, varitess, CLASSIC, CLASSIC CREST, ESSE ENVIRONMENT, ROYAL SUNDANCE, ASTROBRIGHTS, EXACT BRIGHTS, CAPITOL BOND, CRANE'S BOND, and CRANE'S LETTRA brands. The company sells its products through authorized paper distributors, converters, and direct sales. Neenah Paper, Inc. was founded in 2004 and is headquartered in Alpharetta, Georgi a.
Advisors' Opinion:- [By Rich Duprey]
Specialty-paper maker�Neenah Paper� (NYSE: NP ) �announced yesterday�its third-quarter dividend of $0.20 per share, a�33% increase over the $0.15 per-share payout made last quarter, and comes quickly on the heels of a 25% dividend hike it made with the first-quarter payout.
Top Logistics Stocks To Watch Right Now: National Instruments Corporation(NATI)
National Instruments Corporation designs, manufactures, and sells measurement and automation products to create virtual instrumentation systems for general, commercial, industrial, and scientific applications worldwide. The company sells or licenses application software and modular hardware that combines with industry-standard computers, networks, and third party devices to create measurement, automation, and embedded systems. Its system design software products include LabVIEW to design custom virtual instruments for scientists and engineers and provide data analysis, visualization, and sharing features; LabVIEW Real-Time and LabVIEW FPGA, which are modular software add-ons enabling users to configure their application programs and to build custom hardware devices for measurement or control protocols. The company also offers LabWindows/CVI programming environment for creating test and control applications; and Measurement Studio, which consists of measurement and automati on add-on libraries and additional tools for programmers. Its application software products include NI TestStand, a test management environment; NI VeriStand, a ready-to-use software environment; NI DIAdem that offers configuration-based technical data management, analysis, and report generation tools; and NI Multisim, which offers circuit design technology. In addition, the company provides hardware products and related driver software comprising data acquisition hardware/driver software, PXI modular instrumentation platform, modular instruments, machine vision/image acquisition, motion control, NI RIO hardware platform, industrial communications interfaces, GPIB interfaces/driver software, and VXI controllers/driver software. Further, it offers system configuration and deployment, calibration, warranty and repair, and customer training services, as well as software maintenance and technical support. National Instruments Corporation was founded in 1976 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Brian Pacampara]
What: Shares of scientific tools manufacturer National Instruments (NASDAQ: NATI ) sank 13% today after its quarterly results and guidance missed Wall Street expectations. �
- [By Eric Volkman]
National Instruments (NASDAQ: NATI ) has elected to maintain its dividend. The company declared a distribution of $0.14 per share, to be paid on Sept. 3 to shareholders of record as of Aug. 12. That amount matches each of the company's previous six distributions, the most recent of which was paid at the beginning of June. Before that, National Instruments handed out $0.10 per share.
Top Logistics Stocks To Watch Right Now: Kamada Ltd (KMDA)
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company�� product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Kamada (NASDAQ: KMDA) shares shot up 2.64 percent to $15.37 after the company announced the US proof-of-concept study with Glassia to treat GVHD. - [By Monica Gerson]
Kamada (NASDAQ: KMDA) shares fell 27.54% to $10.00 in pre-market trading after the company reported preliminary Alpha-1 Antitrypsin Phase II/III trial results.
- [By Life Sciences Report]
AF: Kamada Ltd. (KMDA) is a relatively unknown Israeli company that is doing very well. It is listed on the Tel Aviv Stock Exchange and the NASDAQ. It has an intravenous form of a drug for alpha-1 antitrypsin (AAT) deficiency, which causes lung and liver disease, that is partnered with Baxter International Inc. (BAX).
Top Logistics Stocks To Watch Right Now: AZ Electronic Materials SA (AZEM)
AZ Electronic Materials SA is a producer and supplier of specialty chemical materials. AZ operates in four segments: IC Materials, which includes products for use in integrated circuits and devices; Optronics, which includes products used in the production of flat panel displays for use in televisions, computer monitors and similar equipment and light emitting diode technology; Printing and Other, which includes printing and similar products used in photo lithographic processes, and Corporate. The Company�� products enable the manufacture of integrated circuits (ICs) and flat panel displays (FPDs) that are integral to a range of electronic devices and applications, including computers and tablet devices, flat screen televisions, mobile communication devices, industrial and automotive applications and the developing light and energy markets. Advisors' Opinion:- [By Corinne Gretler]
AZ Electronic (AZEM) surged 43 percent, the most since its at least November 2010, after Merck on Dec. 5 said it had agreed to buy the company for about 1.6 billion pounds. Merck added 0.4 percent. Shareholders will get 403.5 pence for each share, Merck said. The price is 53 percent above the Dec. 4 closing level in London trading.
No comments:
Post a Comment